REG - Allergy Therapeutics - Block Listing Interim Review

Allergy TherapeuticsAnnouncement

17/12/2024 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241217:nRSQ4634Qa&default-theme=true

RNS Number : 4634Q  Allergy Therapeutics PLC  17 December 2024

Allergy Therapeutics plc

 

("Allergy Therapeutics", "ATL" or the "Group")

 

Block Listing Interim Review

 

 

 Name of applicant:                                                                  ALLERGY THERAPEUTICS PLC
 Name of scheme:                                                                     Allergy Therapeutics plc 2013 Long Term Incentive Plan
 Period of return:                         From:                                     1 October 2023              To:                          17 December 2024
 Number and class of share(s) (amount of stock / debt securities) originally         10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on
 listed and the date of admission:                                                   24 November 2017

                                                                                     Additional listing of 7,000,000 ordinary shares of 0.1p each in the Company
                                                                                     admitted to trading on 7 April 2021

                                                                                     Additional listing of 5,000,000 ordinary shares of 0.1p each in the Company
                                                                                     admitted to trading on 3 October 2023

 Balance of unallotted securities under scheme(s) from previous return:              12,013,147 ordinary shares
 Plus:  The amount by which the block scheme(s) has been increased since the
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period:          12,013,147 ordinary shares of 0.1p each
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:          Nil

 

 Name of contact:              Karley Cheesman
 Telephone number of contact:  +44 (0) 1903 844 700

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com
(mailto:allergytherapeutics@icrhealthcare.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the potential to
cure disease. The Group sells proprietary and third-party products from its
subsidiaries in nine major European countries and via distribution agreements
in an additional ten countries. For more information, please see
www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLREAKAXFFELFFA